Breaking News Instant updates and real-time market news.

AVXL

Anavex

$3.88

0.13 (3.47%)

, LLY

Eli Lilly

$69.12

1.12 (1.65%)

08:01
11/28/16
11/28
08:01
11/28/16
08:01

Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim

After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.

AVXL

Anavex

$3.88

0.13 (3.47%)

LLY

Eli Lilly

$69.12

1.12 (1.65%)

  • 29

    Nov

  • 04

    Dec

AVXL Anavex
$3.88

0.13 (3.47%)

11/30/15
MAXM
11/30/15
NO CHANGE
Target $15
MAXM
Buy
Anavex publishes positive data for ANAVEX 3-71, says Maxim
Maxim analyst Jason Kolbert said Anavex announced additional positive data for ANAVEX 3-71 in the respected journal, Neurodegenerative Diseases. Kolbert said the data provided more upstream effect on reducing syanptic loss, amyloid and tau pathologies, and neuroinflammation, which is potentially beneficial for the treatment of Alzheimer's and other neurological diseases. The analyst rates Anavex a Buy with a $15 price target on shares.
12/30/15
MAXM
12/30/15
NO CHANGE
Target $15
MAXM
Buy
Anavex subpoena not related to wrongdoing by company, says Maxim
Maxim analyst Jason Kolbert said he does not believe the SEC subpoena disclosed yesterday by Anavex involves any wrongdoing by the company or its management. The analyst, who notes that ANAVEX 2-73 continues to show signs of early efficacy in Alzheimer's disease, keeps Buy rating and $15 price target on the stock.
03/29/16
FBRC
03/29/16
INITIATION
Target $10
FBRC
Outperform
Anavex initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Anavex Life Sciences with an Outperform rating and $10 price target.
LLY Eli Lilly
$69.12

1.12 (1.65%)

11/25/16
UBSW
11/25/16
NO CHANGE
Target $70
UBSW
Neutral
Eli Lilly price target lowered to $70 from $82 at UBS
UBS analyst Marc Goodman lowered his price target on Eli Lilly to $70 from $82 following the halt of its solanezumab drug trial for Alzheimer's. The analyst removed his sales estimates for solanezumab and said that without its contribution he is less optimistic for top-line growth. Goodman recommends investors stay on the sidelines and reiterated his Neutral rating on Eli Lilly shares.
11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.
11/25/16
ATLE
11/25/16
DOWNGRADE
ATLE
Neutral
Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities
11/28/16
BOFA
11/28/16
NO CHANGE
BOFA
Buy
Eli Lilly removed from US 1 List at BofA/Merrill

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.